190 related articles for article (PubMed ID: 36851522)
1. Oncolytic Measles Virus Encoding MicroRNA for Targeted RNA Interference.
Anker SC; Szczeponik MG; Dessila J; Dittus K; Engeland CE; Jäger D; Ungerechts G; Leber MF
Viruses; 2023 Jan; 15(2):. PubMed ID: 36851522
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.
Leber MF; Bossow S; Leonard VH; Zaoui K; Grossardt C; Frenzke M; Miest T; Sawall S; Cattaneo R; von Kalle C; Ungerechts G
Mol Ther; 2011 Jun; 19(6):1097-106. PubMed ID: 21468006
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus.
Baertsch MA; Leber MF; Bossow S; Singh M; Engeland CE; Albert J; Grossardt C; Jäger D; von Kalle C; Ungerechts G
Cancer Gene Ther; 2014 Sep; 21(9):373-80. PubMed ID: 25145311
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulation in Oncolytic Measles Virotherapy.
Dietz L; Engeland CE
Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
[TBL] [Abstract][Full Text] [Related]
5. Mitophagy enhances oncolytic measles virus replication by mitigating DDX58/RIG-I-like receptor signaling.
Xia M; Gonzalez P; Li C; Meng G; Jiang A; Wang H; Gao Q; Debatin KM; Beltinger C; Wei J
J Virol; 2014 May; 88(9):5152-64. PubMed ID: 24574393
[TBL] [Abstract][Full Text] [Related]
6. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.
Hutzen B; Bid HK; Houghton PJ; Pierson CR; Powell K; Bratasz A; Raffel C; Studebaker AW
BMC Cancer; 2014 Mar; 14():206. PubMed ID: 24646176
[TBL] [Abstract][Full Text] [Related]
7. Measles virus for cancer therapy.
Russell SJ; Peng KW
Curr Top Microbiol Immunol; 2009; 330():213-41. PubMed ID: 19203112
[TBL] [Abstract][Full Text] [Related]
8. Insert Stability and In Vivo Testing of MicroRNA-Detargeted Oncolytic Picornaviruses.
Schulze AJ
Methods Mol Biol; 2020; 2058():77-94. PubMed ID: 31486032
[TBL] [Abstract][Full Text] [Related]
9. Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.
Bastin D; Aitken AS; Pelin A; Pikor LA; Crupi MJF; Huh MS; Bourgeois-Daigneault MC; Bell JC; Ilkow CS
J Immunother Cancer; 2018 Jun; 6(1):62. PubMed ID: 29921327
[TBL] [Abstract][Full Text] [Related]
10. Engineering and combining oncolytic measles virus for cancer therapy.
Leber MF; Neault S; Jirovec E; Barkley R; Said A; Bell JC; Ungerechts G
Cytokine Growth Factor Rev; 2020 Dec; 56():39-48. PubMed ID: 32718830
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic measles virus strains as novel anticancer agents.
Msaouel P; Opyrchal M; Domingo Musibay E; Galanis E
Expert Opin Biol Ther; 2013 Apr; 13(4):483-502. PubMed ID: 23289598
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-Detargeted Mengovirus for Oncolytic Virotherapy.
Ruiz AJ; Hadac EM; Nace RA; Russell SJ
J Virol; 2016 Apr; 90(8):4078-4092. PubMed ID: 26865716
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of oncolytic measles virus: promises and challenges.
Galanis E
Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites.
Leber MF; Baertsch MA; Anker SC; Henkel L; Singh HM; Bossow S; Engeland CE; Barkley R; Hoyler B; Albert J; Springfeld C; Jäger D; von Kalle C; Ungerechts G
Mol Ther Oncolytics; 2018 Jun; 9():30-40. PubMed ID: 29988512
[TBL] [Abstract][Full Text] [Related]
15. Opportunities to debottleneck the downstream processing of the oncolytic measles virus.
Loewe D; Dieken H; Grein TA; Weidner T; Salzig D; Czermak P
Crit Rev Biotechnol; 2020 Mar; 40(2):247-264. PubMed ID: 31918573
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic measles virus strains in the treatment of gliomas.
Allen C; Paraskevakou G; Liu C; Iankov ID; Msaouel P; Zollman P; Myers R; Peng KW; Russell SJ; Galanis E
Expert Opin Biol Ther; 2008 Feb; 8(2):213-20. PubMed ID: 18194077
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus.
Allagui F; Achard C; Panterne C; Combredet C; Labarrière N; Dréno B; Elgaaied AB; Pouliquen D; Tangy F; Fonteneau JF; Grégoire M; Boisgerault N
Curr Gene Ther; 2017; 16(6):419-428. PubMed ID: 28042780
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Applications for Oncolytic Self-Replicating RNA Viruses.
Lundstrom K
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555262
[TBL] [Abstract][Full Text] [Related]
19. Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S; Bailey K; Fielding A
Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
[TBL] [Abstract][Full Text] [Related]
20. Robust envelope exchange platform for oncolytic measles virus.
Neault S; Bossow S; Achard C; Bell JC; Diallo JS; Leber MF; Ungerechts G
J Virol Methods; 2022 Apr; 302():114487. PubMed ID: 35104497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
